within Pharmacolibrary.Drugs.ATC.D;

model D11AX27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.5,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oxymetazoline is an imidazoline derivative acting as a selective alpha-1 adrenergic receptor agonist and partial alpha-2 agonist, used primarily as a topical decongestant for nasal congestion and, more recently, in topical creams for rosacea and eye drops for redness. It is approved for current clinical use as a nasal spray, ophthalmic solution, and topical dermatological preparation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult after topical (cutaneous) administration; no specific published human PK data found for this cutaneous route. Values are estimated from related nasal/ophthalmic human data and animal data, extrapolated for cutaneous application.</p><h4>References</h4><ol><li><p>Hoover, RM, &amp; Erramouspe, J (2018). Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea. <i>The Annals of pharmacotherapy</i> 52(3) 263–267. DOI:<a href=&quot;https://doi.org/10.1177/1060028017740139&quot;>10.1177/1060028017740139</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29094614/&quot;>https://pubmed.ncbi.nlm.nih.gov/29094614</a></p></li><li><p>Kuang, AW, et al., &amp; Ahluwalia, G (2018). Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. <i>Journal of drugs in dermatology : JDD</i> 17(2) 213–220. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29462230/&quot;>https://pubmed.ncbi.nlm.nih.gov/29462230</a></p></li><li><p>Okwundu, N, et al., &amp; Feldman, SR (2021). Difference in vasoconstrictors: oxymetazoline vs. brimonidine. <i>The Journal of dermatological treatment</i> 32(2) 137–143. DOI:<a href=&quot;https://doi.org/10.1080/09546634.2019.1639606&quot;>10.1080/09546634.2019.1639606</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31294643/&quot;>https://pubmed.ncbi.nlm.nih.gov/31294643</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D11AX27;
